US Patent 9,629,861: What the Claims Actually Cover and How It Sits in the Ceftaroline Landscape
US Drug Patent 9,629,861 claims formulations of ceftaroline (or prodrugs) with a tightly constrained level of an L-arginine adduct used to treat bacterial infections. The patent’s enforceable scope is driven by two quantitative and structural claim elements: (i) dose range of ceftaroline (or prodrug) and (ii) adduct level cap (less than 2% of the pharmaceutical composition), with further narrowing to infection types and specific microorganisms.
What is claimed, in enforceable terms?
Core claim structure (Claims 1 and 2)
Claims 1 and 2 are composition claims with the same dosing framework and the same threshold requirement, differing by the formula for the L-arginine adduct.
Claim 1
- Pharmaceutical composition
- Active: ceftaroline or a prodrug thereof
- Use: treatment of a bacterial infection
- Dose: composition comprises about 200 mg to about 800 mg of ceftaroline (or prodrug)
- Impurity/related species: includes an amount of the L-arginine adduct of Formula I
- Quantitative limitation: the amount of Formula I adduct is less than about 2% of the pharmaceutical composition
Claim 2
- Same structure as claim 1
- Adduct defined as L-arginine adduct of Formula II
- Same quantitative limitation: less than about 2%
Key enforcement lever: the claims turn on an impurity-species level (adduct below a threshold), not only on drug identity or indication.
Use and narrowing limitations (Claims 3, 5, 7)
- Claim 3: infection is limited to either
- complicated skin and skin structure infection (cSSSI), or
- community-acquired bacterial pneumonia (CABP)
- Claim 5: cSSSI-specific
- Claim 7: CABP-specific
These are typical “selection” claim layers that narrow the field to specified clinical contexts.
Proximity to ceftaroline prodrugs (Claim 4)
- Claim 4: ceftaroline or prodrug is limited to ceftaroline fosamil
This is material for market design because fosamil is the known prodrug used in approved ceftaroline regimens.
Microorganism lists (Claims 6 and 8)
Claim 6 (cSSSI microorganisms) includes:
- Staphylococcus aureus
- Streptococcus pyogenes
- Streptococcus agalactiae
- Streptococcus dysgalactiae
- Streptococcus anginosus
- Streptococcus intermedius
- Streptococcus constellatus
- Enterococcus faecalis
- Escherichia coli
- Klebsiella pneumoniae
- Klebsiella oxytoca
- Morganella morganii
Claim 8 (CABP microorganisms) includes:
- Streptococcus pneumoniae
- Staphylococcus aureus
- Haemophilus influenzae
- Haemophilus parainfluenzae
- Klebsiella pneumoniae
- Escherichia coli
Key enforcement lever: if an accused product targets the same dosage forms and has L-arginine adduct levels under the <2% threshold, the microorganism recitations can matter for claim-by-claim infringement theories tied to labeled use.
What do the quantitative limits do to claim scope?
Dose window: about 200 mg to about 800 mg
This range is wide enough to cover typical single-unit and multi-unit dosing presentations used for ceftaroline regimens. It also acts as a gating limitation for:
- fixed-dose vials
- reconstituted concentrations expressed per unit composition
- combination products that would need to fall within the 200-800 mg “composition” parameter for the specified active.
Adduct limitation: less than about 2% of composition
This is the main differentiator. It implies:
- the L-arginine adduct is a related species that can form during formulation or handling
- the patent protects formulations with controlled low adduct content
- products with higher adduct content may fall outside literal scope for claims 1 and 2
From a business-risk standpoint, this converts the patent from “drug + indication” to “drug + formulation specification,” where manufacturing controls and analytical method validation become decisive.
How do the claims map to real product design choices?
1) Ceftaroline vs ceftaroline fosamil
Claim 4 locks ceftaroline fosamil into the set of covered actives. If an accused product uses a different ceftaroline prodrug, infringement arguments would focus on whether that prodrug qualifies as “a prodrug thereof” within the claim interpretation.
2) Adduct identity matters (Formula I vs Formula II)
Claims split the adduct concept into two formula-specific embodiments. If an accused formulation forms only one adduct species, the analysis turns on:
- whether the accused adduct matches Formula I or Formula II
- the fraction of that adduct in the composition
- whether it is measured as “amount” consistent with the patent’s definitional context
3) Infection type narrows clinical scope
Even though claims 1 and 2 already recite “treatment of a bacterial infection,” claims 3, 5, and 7 narrow the infection types. This affects:
- labeling
- promotional claims
- evidence of use in litigation
Where does US 9,629,861 fit in the broader ceftaroline patent landscape?
Positioning relative to ceftaroline active and prodrug IP
In most ceftaroline portfolios, foundational protection covers:
- ceftaroline itself (or core structure)
- ceftaroline fosamil (the prodrug used clinically)
- manufacturing and polymorph/formulation concepts
- dosing regimens and method-of-use claims
US 9,629,861 is distinct because it concentrates on a compositional specification related to the L-arginine adduct and enforces a low-adduct constraint in a specific dose range.
Implication for competitive formulations
Competitors designing around this patent typically pursue one or more of:
- changing the formulation pathway so adduct levels exceed or do not meet the “<2%” constraint
- targeting different presentation dose units so the “about 200 mg to about 800 mg” composition requirement is not met
- relying on distinct clinical positioning that falls outside narrower infection and organism selections
- using different prodrug forms not encompassed by the “prodrug thereof” construct (where feasible)
Potential claim vulnerabilities and litigation friction points
1) “About” qualifiers
Both the dose window (“about 200 mg to about 800 mg”) and the adduct threshold (“less than about 2%”) are elastic. In disputes, courts typically focus on:
- how “about” is quantified using patent disclosure
- what analytical methods were used and how measurement uncertainty is handled
- whether the accused product’s validated testing supports a consistent position below the threshold
2) Formula-specific adduct identification
Literal infringement on adduct content requires that the accused adduct corresponds to the claimed Formula I or Formula II. This raises technical questions:
- what exact structure corresponds to each formula
- whether the adduct measured in an accused formulation maps to the same structure class
3) Method-of-use proof
Even for composition claims, enforcement often turns on product administration and labeling alignment with the claimed bacterial infection categories. The narrower claims (3, 5, 7, 6, 8) increase reliance on labeling and substantiation.
Landscape snapshot: what matters for freedom-to-operate (FTO)
Claim coverage checklist for an accused product
A product most likely to present infringement exposure on US 9,629,861 would satisfy all of the following:
- Active/prodrug: ceftaroline or a prodrug thereof, including ceftaroline fosamil
- Dosage per composition: about 200 mg to about 800 mg of ceftaroline (or prodrug) in the claimed “pharmaceutical composition”
- Adduct control: L-arginine adduct of Formula I or Formula II present at < about 2% of the pharmaceutical composition
- Intended bacterial infection use:
- for narrower claims, cSSSI and/or CABP
- and for narrower microorganism sub-claims, the recited organism list
What most likely drives design-around strategy
- manufacturing and formulation adjustments that increase adduct content above the threshold
- analytical method and specification changes that demonstrate the product does not meet the “<2%” level for the claimed adduct species
- presentation changes that avoid the 200 mg to 800 mg per composition requirement
How strong is the enforceable scope?
The enforceable scope is narrower than broad “ceftaroline for infection” claims because:
- it requires both dose range and adduct content constraints
- it depends on adduct identification (Formula I vs Formula II)
- narrower claims further restrict infection type and microorganisms
The enforceable scope is broader than a pure method-of-use claim because:
- it protects a manufactured composition specification
- it can apply regardless of specific dosing regimens so long as the composition meets the quantitative limits and is used for the claimed indications
Key takeaways
- US 9,629,861 is a formulation-specification patent centered on ceftaroline (including ceftaroline fosamil) plus controlled low levels of an L-arginine adduct.
- Claims 1 and 2 are gated by:
- 200 mg to 800 mg ceftaroline (or prodrug) per pharmaceutical composition, and
- L-arginine adduct of Formula I or II at less than about 2% of the composition.
- Claims 3, 5, 7 narrow covered bacterial infections to cSSSI and CABP.
- Claims 6 and 8 further restrict to enumerated microorganism lists for each infection category.
- The competitive and litigation battleground is likely analytical verification of the exact adduct species and its measured percentage relative to the claimed threshold.
FAQs
1) Does US 9,629,861 claim ceftaroline dosing regimens?
No. It claims pharmaceutical compositions with a specified amount range (about 200 mg to about 800 mg) and a low L-arginine adduct level (< about 2%), paired with treatment of bacterial infections.
2) What is the single most important limitation in claims 1 and 2?
The adduct constraint: L-arginine adduct of Formula I or Formula II at less than about 2% of the pharmaceutical composition.
3) Is ceftaroline fosamil explicitly covered?
Yes. Claim 4 limits the ceftaroline/prodrug to ceftaroline fosamil.
4) Do the claims cover both cSSSI and CABP?
Yes. Claim 3 includes both, while claims 5 and 7 are specific to cSSSI and CABP, respectively.
5) How do microorganism lists affect infringement risk?
They narrow the scope for the narrower dependent claims (claim 6 for cSSSI organisms, claim 8 for CABP organisms), making labeled/used organism coverage a key factor.
References
[1] US Patent 9,629,861, claims 1-8 (as provided in the prompt).
